Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johann Sebastian de Bono

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2011
Prostate cancer: evolution or revolution?Eric J Small, Johann Sebastian de Bono
Cancer Cell|May 18, 2011
Beyond hormone therapy for prostate cancer with PARP inhibitorsJohann Sebastian de Bono, Shahneen Sandhu, Gerhardt Attard
The Oncologist|November 4, 2011
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel settingOliver Sartor, Ross M Michels, Christophe Massard, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|October 13, 2019
Genetic Analysis of Circulating Tumour CellsMichael Paul Kolinsky, Nikolas Stoecklein, Maryou Lambros, et al.
British Journal of Cancer|October 16, 2018
Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centreBrent O'Carrigan, Joline Si Jing Lim, Awais Jalil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2007
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancerJohann Sebastian de Bono, Joaquim Bellmunt, Gerhardt Attard, et al.
BMC Cancer|March 9, 2021
Correction to: Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic diseaseDearbhaile Catherine Collins, Raghav Sundar, Anastasia Constantinidou, et al.
BMC Cancer|December 10, 2020
Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic diseaseDearbhaile Catherine Collins, Raghav Sundar, Anastasia Constantinidou, et al.
Lancet (London, England)|October 5, 2010
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialJohann Sebastian de Bono, Stephane Oudard, Mustafa Ozguroglu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2012
A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumorsUdai Banerji, Leni van Doorn, Dionysis Papadatos-Pastos, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2011
Prostate cancer: evolution or revolution?Eric J Small, Johann Sebastian de Bono
Cancer Cell|May 18, 2011
Beyond hormone therapy for prostate cancer with PARP inhibitorsJohann Sebastian de Bono, Shahneen Sandhu, Gerhardt Attard
The Oncologist|November 4, 2011
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel settingOliver Sartor, Ross M Michels, Christophe Massard, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|October 13, 2019
Genetic Analysis of Circulating Tumour CellsMichael Paul Kolinsky, Nikolas Stoecklein, Maryou Lambros, et al.
British Journal of Cancer|October 16, 2018
Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centreBrent O'Carrigan, Joline Si Jing Lim, Awais Jalil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2007
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancerJohann Sebastian de Bono, Joaquim Bellmunt, Gerhardt Attard, et al.
BMC Cancer|March 9, 2021
Correction to: Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic diseaseDearbhaile Catherine Collins, Raghav Sundar, Anastasia Constantinidou, et al.
BMC Cancer|December 10, 2020
Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic diseaseDearbhaile Catherine Collins, Raghav Sundar, Anastasia Constantinidou, et al.
Lancet (London, England)|October 5, 2010
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialJohann Sebastian de Bono, Stephane Oudard, Mustafa Ozguroglu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2012
A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumorsUdai Banerji, Leni van Doorn, Dionysis Papadatos-Pastos, et al.
Pageof 2